iC9-CAR.B7-H3 T cells

Phase 1Cell therapy

UUNC Lineberger Comprehensive Cancer Center

iC9-CAR.B7-H3 T cells is one of 100 biologic programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

T CellsRecruiting

Ovarian CancerRecruiting

Breast CancerPhase 1

Recruiting

T CellsPhase 1

Recruiting

Ovarian CancerPhase 1

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Voltaren

Novartis

Preclinical

1 2

Zolymbus

AbbVie

Preclinical

1 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Tricor

JJagotec

Preclinical

1 9

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Acupan

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

T Cells

NCT06158139

Phase 1Recruiting

Breast Cancer

NCT06347068

Clinical

Trials by Indication[1]

T Cells1 trial

Autologous CAR-T Cells Targeting B7-H3 in PDAC

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06158139·27 enrolled

Ovarian Cancer1 trial

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06305299·27 enrolled

Breast Cancer1 trial

Study of Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors and Containing the Inducible Caspase 9 Safety Switch in Subjects With Triple Negative Breast Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06347068·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for iC9-CAR.B7-H3 T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iC9-CAR.B7-H3 T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iC9-CAR.B7-H3 T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: UUNC Lineberger Comprehensive Cancer Center

iC9-CAR.B7-H3 T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

T Cells1 trial

Ovarian Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News